Innovo Therapeutics synthesizes new NMT1 inhibitors

▤ Summary

Innovo Therapeutics disclosed new sulfonamide derivatives that inhibit NMT1, a target of interest in cancer, protozoal, and viral disease research. The article frames the compounds as potentially useful for future therapeutic development rather than as a commercial product release. This is relevant to the pharma and life sciences software audience because it signals ongoing R&D activity in a software-adjacent drug discovery segment. No immediate transaction or staffing event is described.

▦ Linked Companies